1: Apolzan JW, LaRose JG, Anton SD, Beyl RA, Greenway FL, Wickham EP 3rd, Lanoye A, Harris MN, Martin CK, Bullard T, Foster GD, Cardel MI. A scalable, virtual weight management program tailored for adults with type 2 diabetes: effects on glycemic control. Nutr Diabetes. 2023 Apr 6;13(1):3. doi: 10.1038/s41387-023-00234-6. PMID: 37024467; PMCID: PMC10079927.
2: Rebello CJ, Coulter AA, Reaume AG, Cong W, Cusimano LA, Greenway FL. MLR-1023 Treatment in Mice and Humans Induces a Thermogenic Program, and Menthol Potentiates the Effect. Pharmaceuticals (Basel). 2021 Nov 22;14(11):1196. doi: 10.3390/ph14111196. PMID: 34832978; PMCID: PMC8625945.
3: Lipinski CA, Reaume AG. High throughput in vivo phenotypic screening for drug repurposing: Discovery of MLR-1023 a novel insulin sensitizer and novel Lyn kinase activator with clinical proof of concept. Bioorg Med Chem. 2020 May 1;28(9):115425. doi: 10.1016/j.bmc.2020.115425. Epub 2020 Mar 16. PMID: 32201192.
4: Lee MK, Kim SG, Watkins E, Moon MK, Rhee SY, Frias JP, Chung CH, Lee SH, Block B, Cha BS, Park HK, Kim BJ, Greenway F. A novel non-PPARgamma insulin sensitizer: MLR-1023 clinicalproof-of-concept in type 2 diabetes mellitus. J Diabetes Complications. 2020 May;34(5):107555. doi: 10.1016/j.jdiacomp.2020.107555. Epub 2020 Feb 2. PMID: 32019723.
5: Ding Y, Li C, Zhang Y, Ma P, Zhao T, Che D, Cao J, Wang J, Liu R, Zhang T, He L. Quercetin as a Lyn kinase inhibitor inhibits IgE-mediated allergic conjunctivitis. Food Chem Toxicol. 2020 Jan;135:110924. doi: 10.1016/j.fct.2019.110924. Epub 2019 Oct 28. Erratum in: Food Chem Toxicol. 2020 Oct;144:111653. doi: 10.1016/j.fct.2020.111653. PMID: 31672514.
6: Ochman AR, Lipinski CA, Handler JA, Reaume AG, Saporito MS. The Lyn kinase activator MLR-1023 is a novel insulin receptor potentiator that elicits a rapid- onset and durable improvement in glucose homeostasis in animal models of type 2 diabetes. J Pharmacol Exp Ther. 2012 Jul;342(1):23-32. doi: 10.1124/jpet.112.192187. Epub 2012 Mar 19. PMID: 22431203.